Moderna price target lowered to $33 from $40 at JPMorgan

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza estimates. The firm now models 2025 RSV sales of about $148M, versus a prior estimate of about $210M, and for FY25 it now models total revenue of $2.1B, versus consensus of $2.2B and just above the $2B guidance midpoint, the analyst tells investors.